1 |
Grann VR, Trovel AB, Zojualla NJ, et al (2005). Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer, 103, 2241-51.
DOI
ScienceOn
|
2 |
Ferrero JM, Ramaioli A, Formento JL, et al (2000). p53 determination alongside classical prognostic factors in nodenegative breast cancer: An evaluation at more than 10-year follow- up. Ann Oncol, 11, 393-7.
DOI
ScienceOn
|
3 |
Goldhirsch A, Wood WC, Gelber RD, et al (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol, 18, 1133-44.
DOI
ScienceOn
|
4 |
Gonzales-Angulo AM, Litton JK, Broglio KR, et al (2009). High risk of recurrence for patientswith breast cancer who have human epidermal growth factor receptor 2- positive, nodenegative tumors 1 cm or smaller. J Clin Oncol, 27, 5700-6.
DOI
ScienceOn
|
5 |
Joensuu H, Bono P, Kataja V, et al (2009). Fluorouracil, epirubisin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adhuvant treatments of breast cancer: final results of the FinHer study. J Clin Oncol, 27, 5685-92.
DOI
ScienceOn
|
6 |
Carter C, Allen C, Henson D (1989). Relation of tumor size, lymph node and survival in 24 740 breast cancer cases. Cancer, 63, 181-7.
DOI
|
7 |
Curigliano G, Viale G, Bagnari V, et al (2009). Clinical relevance of Her2 overexpresion/ amplification in patients with small tumour size and node-negative breast cancer. J Clin Oncol, 27, 5693-99.
DOI
ScienceOn
|
8 |
Dowsett M, Allred C, Knox J, et al (2008). Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor-2 (Her2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol, 26, 1059-65.
DOI
ScienceOn
|
9 |
Drukker CA, Bueno-de-Mesquita JM, Retel VP, et al (2013). A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer, 133, 929-36.
DOI
ScienceOn
|
10 |
Dunnwold LK, Rossing MA, Li CI (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 9, 6-9.
|
11 |
Early Breast Cancer Trialists' Collaborative Group (1998). Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 351, 1451-67.
DOI
ScienceOn
|
12 |
Weigel MT, Dowsett M (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer, 17, 245-62.
DOI
ScienceOn
|
13 |
Rakha EA, Martin S, Lee AHS, et al (2012). The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer, 118, 3670-80.
DOI
|
14 |
Taneja P, Maglic D, Kai F, et al (2010). Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights: Oncol, 4, 15-34.
|
15 |
Truong PT, Vinh-Hung V, Cserni G, et al (2008). The number of positive nodes and the ratio of positive to excised nodes are significant predictors of sur-vival in women with micrometastatic node-positive breast cancer. Eur J Cancer, 44, 1670-7.
DOI
|
16 |
Viale G, Regan MM, Maiorano E, et al (2007). Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG- I-98. J Clin Oncol, 25, 3846-52.
DOI
|
17 |
Kroger N, Milde-Langosh K, Riethdorf S, et al (2006). Prognostic and predictive effects of immunohistochemical factors in high risk primary breast cancer patients. Clin Cancer Res, 12, 159-68.
DOI
ScienceOn
|
18 |
Lai HW, Kuo SJ, Chen LS, et al (2011). Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol, 37, 18-24.
DOI
|
19 |
Nishimura R, Arima N (2008). Is triple negative a prognostic factor in breast cancer? Breast Cancer, 15, 303-8.
DOI
|
20 |
Reinke T (2013). Poor risk assessment limits breast cancer survival. Manag Care, 22, 6-7.
|
21 |
Rodrigues MJ, Wassermann J, Albiges L, et al (2010). Trastuzumab treatment in T1ab, node-negative, human epidermal growth factor receptor- 2 -over-expressing breast carcinomas. J Clin Oncol, 28, 541-2.
DOI
|
22 |
Smith I, Practer M, Gelber RD, et al (2007). 2-year follow- up of trastuzumab after adjuvant chemotherapy in Her2 positive breast cancer: a randomized controlled trial. Lancet, 39, 29-36.
|
23 |
Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman J (1989). Pathological prognostic fac-tors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinomas: a study of 644 patients with median follow-up of 18 years. J Clin Oncol, 7, 1239-51.
|
24 |
Rosen PP, Groshen S, Kinne DW (1992). Survival and prognostic factors in node-negative breast cancer: results of long-term follow-up studies. J Natl Cancer Inst Monogr, 11, 159-62.
|
25 |
Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
DOI
ScienceOn
|
26 |
Jung KW, Won YJ, Kong HJ, et al (2013). Survival of korean adults patientsby stage at diagnosis, 2006-2010; national cancer registry study. Cancer Res Treat, 45, 162-71.
DOI
ScienceOn
|